Phase Ib Trial of Teclistamab and Iberdomide in Relapsed/Refractory Multiple Myeloma
A phase Ib trial is underway to evaluate the safety and dosing of iberdomide combined with teclistamab for relapsed or refractory multiple myeloma.
Phase III
National Cancer Institute
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The ongoing phase Ib trial of teclistamab and iberdomide represents a significant opportunity to enhance treatment options for relapsed or refractory multiple myeloma. This combination could address unmet medical needs and strengthen competitive positioning in a crowded therapeutic landscape.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor trial results for safety and efficacy data, as well as any subsequent regulatory filings.
Related companies & assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.